Seres Therapeutics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Seres Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 140.79% higher than the current stock price, while the lowest is $12 (+69.97%) and the highest is $22 (+211.61%).

Price Target: $17 (+140.79%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$12	$17	$17	$22
Change	+69.97%	+140.79%	+140.79%	+211.61%

Analyst Ratings

The average analyst rating for Seres Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Feb '26	Mar '26	May '26	Jun '26
Strong Buy	2	1	1	1	1	2
Buy	0	0	0	0	0	0
Hold	2	2	2	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	3	3	1	1	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Keller H.C. Wainwright	H.C. Wainwright	Buy Initiates $12	Buy	Initiates	$12	+69.97%	Jun 23, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $22	Buy	Maintains	$22	+211.61%	May 6, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Hold Maintains $20	Hold	Maintains	$20	+183.29%	Feb 13, 2026

Financial Forecast

Revenue This Year

12.86M

from 789.00K

1,529.66%

from 789.00K

Revenue Next Year

358.00K

from 12.86M

-97.22%

from 12.86M

EPS This Year

-7.52

from 0.64

EPS Next Year

-6.58

from -7.52

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	144.93M	-	-	-	789.00K	12.86M
Revenue Growth	336.33%	-	-	-	-	1,529.66%
Gross Profit	3.04M	-109.65M	-117.60M	-68.13M	-54.82M	12.53M
Gross Margin	2.09%	-	-	-	-6,947.40%	97.42%
Operating Income	-64.49M	-179.91M	-195.10M	-121.32M	-93.97M	-78.20M
Net Income	-65.58M	-250.16M	-113.72M	136.00K	5.70M	-70.97M
EPS	-	-	-	-	0.64	-7.52
Free Cash Flow	14.04M	-87.82M	-112.46M	-60.11M	-54.96M	-5.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	25.0M
Avg	12.9M
Low	716,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	3,068.6%
Avg	1,529.7%
Low	-9.3%

EPS Forecast

EPS	2026	2027	2028
High	-5.84
Avg	-7.52
Low	-9.19

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-